baudax bio, inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed phase iii clinical trials for the management of moderate to severe pain; and is in the phase iiib clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. the company's early-stage product candidates includes rp1000, an intermediate-acting neuromuscular blocking agent (nmba) that is in phase i clinical trial; and rp2000, an ultrashort-acting nmba, which is in pre-clinical trial; and a reversal agent, as well as dex-in, a proprietary intranasal formulation of dexmedetomidine. the company was incorporated in 2019 and is based in malvern, pennsylvania.
Company profile
Ticker
BXRXQ
Exchange
Website
CEO
Gerri A. Henwood
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Recro Enterprises, Inc.
SEC CIK
Corporate docs
Subsidiaries
Baudax Bio N.A. LLC • Baudax Bio Limited ...
IRS number
474639500
BXRXQ stock data
Latest filings (excl ownership)
8-K
Bankruptcy or Receivership
28 Feb 24
25-NSE
Exchange delisting
15 Feb 24
8-K
Other Events
12 Dec 23
424B3
Prospectus supplement
22 Nov 23
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Nov 23
8-K
Changes in Registrant's Certifying Accountant
25 Oct 23
8-K
Submission of Matters to a Vote of Security Holders
13 Oct 23
DEFA14A
Additional proxy soliciting materials
10 Oct 23
Transcripts
BXRXQ
Earnings call transcript
2022 Q1
7 May 22
BXRXQ
Earnings call transcript
2021 Q3
4 Nov 21
BXRXQ
Earnings call transcript
2021 Q2
8 Aug 21
BXRXQ
Earnings call transcript
2021 Q2
5 Aug 21
BXRXQ
Earnings call transcript
2021 Q1
5 May 21
BXRXQ
Earnings call transcript
2020 Q4
16 Feb 21
BXRXQ
Earnings call transcript
2020 Q3
9 Nov 20
BXRXQ
Earnings call transcript
2020 Q3
9 Nov 20
BXRXQ
Earnings call transcript
2020 Q2
10 Aug 20
Latest ownership filings
SC 13G/A
BLACK HORSE CAPITAL LP
14 Feb 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
3
Natalie McAndrew
11 Oct 23
3
Yong Chan Kim
13 Jul 23
SC 13G/A
BLACK HORSE CAPITAL LP
10 Jul 23
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
INTRACOASTAL CAPITAL, LLC
8 Feb 23
4
GERALDINE HENWOOD
19 Dec 22
SC 13G
INTRACOASTAL CAPITAL, LLC
6 Sep 22
4
William Ashton
17 Jun 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 363.00 k | 363.00 k | 363.00 k | 363.00 k | 363.00 k | 363.00 k |
Cash burn (monthly) | 351.00 k | 440.33 k | 592.00 k | 4.61 mm | 790.00 k | 2.03 mm |
Cash used (since last report) | 3.78 mm | 4.74 mm | 6.38 mm | 49.68 mm | 8.51 mm | 21.88 mm |
Cash remaining | -3.42 mm | -4.38 mm | -6.01 mm | -49.32 mm | -8.15 mm | -21.52 mm |
Runway (months of cash) | -9.7 | -9.9 | -10.2 | -10.7 | -10.3 | -10.6 |
Institutional ownership, Q1 2024
0.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 439.00 k |
Total shares | 402.09 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Black Horse Capital | 375.00 k | $439.00 k |
Intracoastal Capital | 27.09 k | $0.00 |